key: cord-0281073-q4raoz8x
authors: Colavita, F.; Meschi, S.; Gruber, C. E. M.; Rueca, M.; Vairo, F.; Matusali, G.; Lapa, D.; Giombini, E.; De Carli, G.; Spaziante, M.; Messina, F.; Bonfiglio, G.; Carletti, F.; Lalle, E.; Fabeni, L.; Berno, G.; Puro, V.; Di Caro, A.; Bartolini, B.; Ippolito, G.; Capobianchi, M. R.; Castilletti, C.; team, INMI Covid-19 laboratory surveillance
title: Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination.
date: 2021-09-22
journal: nan
DOI: 10.1101/2021.09.21.21263882
sha: 5eec0bbb35dd46fb57c37fd7260f7007d6be0d6b
doc_id: 281073
cord_uid: q4raoz8x

Coronavirus disease 2019 (COVID-19) vaccines are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study describes 94 infections (47.9% symptomatic, 52.1% asymptomatic), occurred in Lazio Region (Central Italy) in the first trimester 2021, after first or second dose of mRNA BNT162b2 vaccine. Median viral load at diagnosis was independent from number and time of vaccine dose administration, despite the higher proportion of samples with low viral load observed in fully vaccinated individuals. More importantly, infectious virus was cultured from NPS collected from both asymptomatic and symptomatic vaccinated individuals, suggesting that, at least in principle, they can transmit the infection to susceptible people. The majority of the post-vaccine infections here reported, showed pauci/asymptomatic clinical course, confirming the impact of vaccination on COVID-19 disease. Most cases (78%) showed infection in presence of neutralizing antibodies at the time of infection diagnosis, presumably attributable to vaccination, due to the concomitant absence of anti-N IgG in most cases. The proportion of post-vaccine infections attributed either to Alpha and Gamma VOCs was similar to the proportion observed in the contemporary unvaccinated population in Lazio region. In addition, mutational analysis did not suggest enrichment of a defined set of Spike protein substitutions depending on the vaccination status. Characterization of host and virus factors associated with vaccine breakthrough, coupled with intensive and continuous monitoring of involved viral strains, is crucial to adopt informed vaccination strategies.

In less than 12 months after the beginning of the COVID-19 pandemic, scientific research 45 succeeded in developing multiple vaccines against a previously unknown viral pathogen, severe 46 acute respiratory coronavirus 2 (SARS-CoV-2). The mRNA-based Pfizer-BioNTech vaccine (BNT162b2) has been the first authorized, and on 27 December 2020, the European Union 48 countries launched a co-ordinated vaccination campaign that initially was prioritized for individuals 49 at high risk of SARS-CoV-2 exposure, such as the health-care workers (HCW), and for those at 50 high risk of severe COVID-19, including elderly and residents of assisted living facilities. One key 51 point is to identify and follow up post-vaccine infections and to assess vaccine effectiveness in 52 reducing disease severity and limiting infection transmission to unvaccinated individuals. As 53 expected due to the fact that COVID-19 vaccines do not offer 100% protection against the SARS-54

CoV-2 infection, current evidence showed that individuals who received full vaccination can 55 become infected 1 ; however, they seem to have lower risk to develop severe COVID-19 compared 56 to unvaccinated people, and to carry reduced viral loads with a likely lower transmission to others 57 infected after a single dose as compared to patients infected after full vaccination course; a trend 182 towards less frequent severe course was observed in infections acquired after two doses. 183

Median Ct values of NPS at diagnosis was 21.2 (IQR: 17.5-31.3), with no significant difference 186 between asymptomatic and symptomatic presentation (median Ct values: 22.0 vs 19.6, Figure  187 1A), even in those patients tested positive after full vaccine course (median Ct values: 21.8 vs 188

18.9; Figure 1A ). To understand whether viral RNA was associated to infectiousness, virus 189 isolation was attempted on 84 NPS; 10 NPS were not tested due to due to viral infectivity 190 inactivation by guanidine isothiocyanate contained in the transport medium used for sample 191 collection. Notably, infectious virus was rescued from 44 (52.4%) NPS, 24 collected from 192 symptomatic individuals, 20 collected from asymptomatic subjects. No significant difference in 193 culture positivity rates were found between these two groups (54.5% in symptomatic vs 50.0% in 194 asymptomatic, p=0.827). Similar results were obtained when considering fully vaccinated patients 195 only (60.9% in symptomatic vs 48.2% in asymptomatic, p=0.567). The proportion of samples with 196 low viral load (Ct values >30) in asymptomatic individuals (32.6%) was higher compared to the 197 symptomatic patients (20.0%), but did not reach statistical significance (p=0.242). 198

We next considered the viral RNA levels according to time lapsed from first dose to diagnosis, 199 known for 79 individuals, who were divided in 3 groups. The results indicated similar median Ct 200 values in all 3 groups (Fig. 1B) , despite the higher proportion of samples with low viral load in 201 Group 3. This finding coupled with the isolation rate, which was found higher in samples collected 202 shortly after the vaccination (Group 1), but did not reach statistical difference compared to the 203 other groups (Group 1: 85.7%, Group 2: 40.0%; Group 3: 54.0%, p=0.411). As shown in detail in 204 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint old and presenting co-morbidities), indicating primary non response to vaccine. Out of 44 samples 218 collected from individuals with known date of vaccination, we observed significant differences in 219 antibody titres, both anti-RBD Spike IgG and nAb ( Figure 3A-B) , along the different time-points 220 from vaccination, with high titres after 15 days from the first dose (Groups 2 and 3). Unexpectedly, 221

Group 2 presented higher antibody levels compared to Group 3, which included fully vaccinated 222 individuals. This difference resulted statistically significant for anti-S IgG (p<0.01), not for 223 neutralizing antibodies. 224

Since anti-N IgG seroconversion at diagnosis was observed only in 3 patients (6.0%), we 225 reasonably argue that the detected functional antibody response was mostly (39/50, 78.0%) 226 elicited by vaccination, and not by the infection per-se. In addition, we have formal evidence of pre-227 infection (38 and 60 days before infection) vaccine-induced antibodies response in two patients, 228

with nAb titers of 1:160 at day 15 from full immunization for both infections. As shown in Figure 3B  229 and Supplementary Table 1 , the presence of nAb in serum did not preclude virus isolation from 230 NPS, and titres were not correlated with viral load (median Ct values: 21.5, 231 Spearman r=0.220, . Notably, data from Table 2 show a trend to negative 232 association of viral isolation rate with high nAb titers (OR=0.28 for nAb ≥1:80 vs <1:80). 233

Considering the immune status in relation to the clinical course of post-vaccination infections, no 234 statistically significant differences in both anti-RBD Spike IgG and nAb median values were found 235 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 amongst the different groups of disease severity (Supplementary Figure 1) , with no significant 236 association between clinical course and presence or high titres (≥1:80) of nAb (p=0.082 and 0.224, 237 respectively). 238

We next investigated the viral variants infecting the vaccinated individuals included in this study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.21.21263882 doi: medRxiv preprint that infectious virus can be cultured from NPS collected from both asymptomatic and symptomatic 291 vaccinated individuals, suggesting that they could be able to transmit the infection to susceptible 292 people and potentially be part of transmission chains. As observed for infections in unvaccinated 293 people, high viral load (Ct≤25) is a strong determinant of isolation success 20,21 . This finding should 294 be carefully considered for public health policy, emphasizing the importance of a proper 295 communication that vaccine does not confer sterilizing immunity; therefore, continued adherence to 296 public health prevention measures is still recommended for vaccinated individuals until adequate 297 vaccination coverage of the population is reached or in presence of susceptible vulnerable 298 individuals 5,22,23 .On the other hand, the very small proportion of post-vaccine infections is 299 encouraging that overall risk of transmission from vaccinated persons will be low, supporting the 300 crucial role of vaccination. 301

The impact of emerging variants on the vaccination campaigns is under investigation as vaccine 302 escape variants may be associated to increased vaccine failure 6 . In the vaccinated individuals 303 In a recent study from Israel, Kustin et al. 24 reported that infection with Beta VOC was 312 disproportionally detected in fully vaccinated individuals, while Alpha VOC was disproportionally 313 involved in infections diagnosed between 2 weeks after the first dose and 6 days after the second 314 dose. The differences with our results may be due to different pattern of VOCs circulation, as, for 315 example, circulation of Beta VOC was very tiny in our territory. In addition, Spike mutations in each 316 lineage, broken down by Groups 1, 2 and 3, indicated that there is no selection for enrichment of 317 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.21.21263882 doi: medRxiv preprint vaccination and prior infection was not available for most of these individuals (except for two 323 cases, who underwent serological testing before the infection), in line with recent report 25 , the nAb 324 titers measured shortly after the infection, together with negative anti-N IgG serology, suggest that 325 it is very likely that they had a immune responses to the vaccine, yet not sufficient to prevent the 326 contagion. On the contrary, 8 individuals tested SARS-CoV-2-positive after vaccination did not 327 present nAb, 2 of them reported as fully vaccinated, suggesting primary non response to vaccine. 328

Unexpectedly, Group 2 presented the highest antibody levels, even compared to Group 3 which 329 included fully vaccinated individuals; while it is reasonable that antibody levels in Group 2 is higher 330 than in Group 1 (due to the longer interval from vaccine administration), the observed difference 331 between Group 2 and 3 seems not to be explained with the available information concerning 332 symptomatic versus asymptomatic infection and distance from symptoms onset, which resulted to 333 be similar between the two groups. A weak response to the vaccination may be a possible 334 explanation. Studies including larger population will help clarify this point. In addition, our data 335

showed that the presence of nAb in serum did not preclude isolation of replication-competent virus 336 from NPS of vaccines; however, the relationship between the infectivity of released virus and the 337 presence of nAb in serum or in the nasopharyngeal tract deserves to be better investigated 338 through dedicated studies. 339

According to previous reports, the majority of infections observed in vaccinated individuals in this 340 study had a mild or asymptomatic clinical course, and those patients with severe symptoms 341 presented pre-existing co-morbidities and lower median antibody levels compared to those who 342 had a mild or asymptomatic presentation. Two deaths were observed, both in patients over 85 343 years old and with multiple co-morbidities, which represent a relevant risk factors for severe 344 disease and are prognostic for negative outcome 4,26-28 . This confirms overall vaccine effectiveness 345 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Our study presents some limitation that should be acknowledged. First, the study was an 349 observational study based on real-life data obtained from pandemic surveillance activities, aimed 350 not to establish vaccine efficacy compared to a matched unvaccinated control group, but, to report is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 culture are indicated in red and black, respectively; empty dots indicate samples for which viral 516 culture was not performed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 classified as pauci/asymptomatic (n=31), mild (n=15), and severe (n=4) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.21.21263882 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.21.21263882 doi: medRxiv preprint Figure S1 . 590 591 592 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-432 New Virus

Signals of hope: gauging the impact of a rapid national 434 vaccination campaign

Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2

Infection Rates than Antibody Negative Healthcare Workers? Large Multi-Centre 437

Prospective Cohort Study (The SIREN Study)

SARS-CoV-2 Infection after Vaccination in Health Care Workers in 440

Interim Estimates of Vaccine Effectiveness of